Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Cardiac Sarcoidosis Response To Steroids Trial

Phase 4

Withdrawn

Conditions: Cardiac Sarcoidosis
Sarcoidosis

Interventions: Drug: Prednisone

First Posted Date: 2010-09-28

Last Posted Date: 2013-10-30

Lead Sponsor: Ottawa Heart Institute Research Corporation

Registration Number: NCT01210677

Locations: 🇨🇦
University of Ottawa Heart Institute, Ottawa, Ontario, Canada

Oral Steroids Before Pulmonary Vein Isolation to Improve Outcomes

Phase 4

Completed

Conditions: Atrial Fibrillation

Interventions: Other: Placebo
Drug: Prednisone
Procedure: Ablation Procedure

First Posted Date: 2010-09-21

Last Posted Date: 2017-05-17

Lead Sponsor: Dhanunjaya Lakkireddy, MD, FACC

Target Recruit Count: 60

Registration Number: NCT01206452

Locations: 🇺🇸
University Of Kansas Medical Center, Kansas City, Kansas, United States

A Study of Olaratumab (IMC-3G3) in Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Biological: Olaratumab
Drug: Prednisone
Drug: Mitoxantrone

First Posted Date: 2010-09-17

Last Posted Date: 2019-09-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 123

Registration Number: NCT01204710

Locations: 🇪🇸
ImClone Investigational Site, Valencia, Spain

Single Dose Study Of PF-04171327 And Prednisone On Carbohydrate Metabolism

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-04171327
Drug: Prednisone

First Posted Date: 2010-09-13

Last Posted Date: 2010-12-17

Lead Sponsor: Pfizer

Target Recruit Count: 18

Registration Number: NCT01199900

Locations: 🇺🇸
Pfizer Investigational Site, Kalamazoo, Michigan, United States

Single Dose Study Of PF-04308515 And Prednisone On Carbohydrate

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-04308515
Drug: Prednisone

First Posted Date: 2010-09-10

Last Posted Date: 2010-12-16

Lead Sponsor: Pfizer

Target Recruit Count: 18

Registration Number: NCT01199029

Locations: 🇺🇸
Pfizer Investigational Site, Kalamazoo, Michigan, United States

Evaluation of Low Dose Corticosteroids Efficiency, Associated With Myfortic ® in the Treatment of Nephrotic Syndrome

Phase 3

Completed

Conditions: Nephrotic Syndrome

Interventions: Drug: acid mycophenolic (Myfortic)
Drug: Prednisone

First Posted Date: 2010-09-09

Last Posted Date: 2017-06-28

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 117

Registration Number: NCT01197040

Locations: 🇫🇷
Henri Mondor Hospital, Creteil, Val de Marne, France

Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas

Phase 1

Completed

Conditions: Ann Arbor Stage I Grade 3 Follicular Lymphoma
Ann Arbor Stage II Diffuse Large B-Cell Lymphoma
Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma
AIDS-Related Plasmablastic Lymphoma
AIDS-Related Primary Effusion Lymphoma
Ann Arbor Stage I Diffuse Large B-Cell Lymphoma
Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma
Ann Arbor Stage III Diffuse Large B-Cell Lymphoma
Ann Arbor Stage III Grade 3 Follicular Lymphoma
Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine Sulfate
Drug: Vorinostat

First Posted Date: 2010-09-02

Last Posted Date: 2023-11-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 107

Registration Number: NCT01193842

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

and more 32 locations